Warnings

Peliosis hepatis, a condition in which liver and sometimes splenic tissue is replaced with blood-filled cysts, has been reported in patients receiving androgenic anabolic steroid therapy. these cysts are sometimes present with minimal hepatic dysfunction, but at other times they have been associated with liver failure. they are often not recognized until life-threatening liver failure or intra-abdominal hemorrhage develops. withdrawal of drug usually results in complete disappearance of lesions.
 
 Liver cell tumors are also reported. most often these tumors are benign and androgen-dependent, but fatal malignant tumors have been reported. withdrawal of drug often results in regression or cessation of progression of the tumor. however, hepatic tumors associated with androgens or anabolic steroids are much more vascular than other hepatic tumors and may be silent until life-threatening intra-abdominal hemorrhage develops.
 
 Blood lipid changes that are known to be associated with increased risk of atherosclerosis are seen in patients treated with androgens and anabolic steroids. these changes include decreased high-density lipoprotein and sometimes increased low-density lipoprotein. the changes may be very marked and could have a serious impact on the risk of atherosclerosis and coronary artery disease.

Hypercalcemia may develop both spontaneously and as a result of androgen therapy in women with disseminated breast carcinoma. If it develops while on this agent, the drug should be discontinued. Caution is required in administering these agents to patients with cardiac, renal or hepatic disease. Cholestatic jaundice is associated with therapeutic use of anabolic and androgenic steroids. Edema may occur occasionally with or without congestive heart failure. Concomitant administration of adrenal steroids or ACTH may add to the edema.

In children, anabolic steroid treatment may accelerate bone maturation without producing compensatory gain in linear growth. This adverse effect may result in compromised adult stature. The younger the child the greater the risk of compromising final mature height. The effect on bone maturation should be monitored by assessing bone age of the wrist and hand every six months.

This drug has not been shown to be safe and effective for the enhancement of athletic performance. Because of the potential risk of serious adverse health effects, this drug should not be used for such purpose




                       
PDF DOWNLOAD      WORD DOCUMENT

Product Enquiry	Product Quotation	Sample Request	Place Your Order